Press Releases
Press Releases
-
October 23, 2020
Gilead Sciences Completes Acquisition of Immunomedics, Inc. -
October 22, 2020
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19 -
October 22, 2020
Anthony Welters Joins Gilead Sciences’ Board of Directors -
October 21, 2020
Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans -
October 19, 2020
Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020 -
October 16, 2020
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma -
October 14, 2020
Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 -
October 14, 2020
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer -
October 12, 2020
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis -
October 8, 2020
Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19